Search results
Q1 2024 Ascelia Pharma AB Earnings Call Transcript
Guru Focus· 7 days agoThank you, and welcome, everyone, to the Q1 report for 2024. At Ascelia Pharma, we identify, develop, and commercialize novel drugs that address unmet medical needs within rare cancer conditions ...
SuVax™ and MarVax™ Thermostable Vaccine Platform to be Presented at the Vaccine Technology IX...
FOX 23 News Albany· 2 days agoSoligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an ...
Q1 2024 Biomx Inc Earnings Call
Thomson Reuters StreetEvents via Yahoo Finance· 24 hours agoIn January this year, we were granted Orphan Drug Designation by the FDA for BX004. More recently, in April, we presented positive safety and efficacy results ...
Moleculin begins NIH-funded Phase II glioblastoma treatment trial
Clinical Trials Arena via Yahoo Finance· 7 days agoWP1066, an immune/transcription modulator, is designed to enhance the immune response to tumours by...
FDA grants breakthrough therapy status for Nuvalent’s NVL-655
Pharmaceutical Technology via Yahoo Finance· 6 days agoUnder BTD, the US regulator offers intensive guidance and the possibility of a rolling review to...
Small Business - Shelby County Reporter | Shelby County Reporter
The Shelby County Reporter· 4 days agoAmgen (NASDAQ:AMGN) and AstraZeneca today announced the results of the Phase 2a COURSE trial evaluating Tezspire® (tezepelumab-ekko) in people with moderate to very severe chronic obstructive ...
FDA lifts hold on Larimar's Friedreich's Ataxia drug study By Investing.com
Investing.com· 2 days agoLarimar Therapeutics, Inc. (NASDAQ:LRMR), a biotechnology firm engaged in developing treatments for...
Adolore BioTherapeutics Outlines Strategy for its Next Generation, Disease-Modifying, Non-Opioid...
Digital Journal· 1 day agoDELRAY BEACH, FL / ACCESSWIRE / May 21, 2024 / Adolore BioTherapeutics ("Adolore" or the "Company"), a biotechnology company focused on developing breakthrough opioid-free gene therapy treatments ...
Earnings call: Longeveron reports Q1 2024 results, optimistic on Lomecel-B
Investing.com· 5 days agoLongeveron Inc. (LGVN), a leader in regenerative medicine, recently discussed its first-quarter...
Adolore BioTherapeutics Announces Publication Demonstrating Carbonic Anhydrase-8 Gene Therapy...
Morningstar· 7 days agoFindings highlight the advantages of Adolore's approach for the delivery of proprietary gene therapy directly to specialized pain-sensing peripheral nerves (nociceptors) that mediate profound ...